Drug Profile


Alternative Names: WR 3689; WR 3689 - phosphothioate

Latest Information Update: 15 Oct 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Chicago
  • Developer Hollis-Eden Pharmaceuticals
  • Class Radioprotectives; Small molecules
  • Mechanism of Action Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Radiation injuries

Most Recent Events

  • 27 Feb 2004 Preclinical trials in Radiation injuries (Prevention)/Radioprotection in USA (unspecified route)
  • 15 Feb 2000 A preclinical study has been added to the pharmacodynamics and adverse events sections
  • 29 Jan 1999 Preclinical development for Radiation injuries (Prevention)/Radioprotection in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top